CI - Cigna Corporation
NYSE
->
Healthcare
->
Healthcare Plans
Bloomfield,
United States
Type: Equity
CI price evolution
CI
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6788 | $8439 | $7822 | |
| Short term investments | $1068 | $1108 | $925 | |
| Net receivables | $27846 | $29706 | $25235 | $22557 |
| Inventory | $5083 | $5173 | $4630 | $5645 |
| Total current assets | $49222 | $46215 | $43357 | $37351 |
| Long term investments | $15944 | $16025 | $17985 | |
| Property, plant & equipment | $3594 | $3551 | $3607 | $3695 |
| Goodwill & intangible assets | $74434 | $74749 | $75122 | |
| Total noncurrent assets | $109231 | $109762 | $115410 | |
| Total investments | $17012 | $17133 | $18910 | |
| Total assets | $157639 | $155446 | $153119 | $152761 |
| Current liabilities | ||||
| Accounts payable | $8515 | $36778 | $32402 | $28368 |
| Deferred revenue | ||||
| Short long term debt | $1717 | $1715 | $2775 | |
| Total current liabilities | $57060 | $55373 | $51977 | $48716 |
| Long term debt | $30230 | $30175 | $31053 | $28155 |
| Total noncurrent liabilities | $58546 | $59792 | $57694 | |
| Total debt | $31892 | $32768 | $30930 | |
| Total liabilities | $115544 | $113919 | $111769 | $106410 |
| Shareholders' equity | ||||
| Retained earnings | $42480 | $42132 | $40978 | $41652 |
| Other shareholder equity | -$2163 | -$2442 | -$2324 | -$1864 |
| Total shareholder equity | $41332 | $41181 | $46223 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7822 | $5924 | $5081 | $10182 |
| Short term investments | $925 | $905 | $920 | $1331 |
| Net receivables | $22557 | $21961 | $20041 | $17391 |
| Inventory | $5645 | $4777 | $3722 | $3165 |
| Total current assets | $37351 | $30120 | $36134 | $27799 |
| Long term investments | $17985 | $16288 | $18438 | $23262 |
| Property, plant & equipment | $3695 | $4149 | $3692 | $4205 |
| Goodwill & intangible assets | $75122 | $78303 | $79913 | $79827 |
| Total noncurrent assets | $115410 | $113812 | $118755 | $127652 |
| Total investments | $18910 | $17193 | $19358 | $24593 |
| Total assets | $152761 | $143932 | $154889 | $155451 |
| Current liabilities | ||||
| Accounts payable | $28368 | $7775 | $21964 | $18825 |
| Deferred revenue | ||||
| Short long term debt | $2775 | $2993 | $2545 | $3374 |
| Total current liabilities | $48716 | $36190 | $43572 | $36022 |
| Long term debt | $28155 | $28100 | $31125 | $29545 |
| Total noncurrent liabilities | $57694 | $57752 | $64133 | $69043 |
| Total debt | $30930 | $31093 | $33670 | $32919 |
| Total liabilities | $106410 | $99060 | $107705 | $105065 |
| Shareholders' equity | ||||
| Retained earnings | $41652 | $37874 | $32593 | $28575 |
| Other shareholder equity | -$1864 | -$1075 | -$884 | -$861 |
| Total shareholder equity | $46223 | $44872 | $47112 | $50321 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $63694 | $57255 | ||
| Cost of revenue | $50871 | |||
| Gross Profit | $6602 | $6384 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $3705 | |||
| Total operating expenses | $3949 | $4128 | ||
| Operating income | $2256 | |||
| Income from continuing operations | ||||
| EBIT | $336 | |||
| Income tax expense | $367 | $291 | ||
| Interest expense | -$1297 | $322 | ||
| Net income | ||||
| Net income | $739 | -$277 | ||
| Income (for common shares) | -$277 | |||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $195265 | $180516 | $160401 | |
| Cost of revenue | $170088 | $157040 | $136194 | |
| Gross Profit | $25177 | $23476 | $24207 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $14822 | $13186 | $14072 | |
| Total operating expenses | $16641 | $13400 | $16054 | |
| Operating income | $8536 | $10076 | $8153 | |
| Income from continuing operations | ||||
| EBIT | $6751 | $9503 | $12275 | |
| Income tax expense | $141 | $1607 | $2379 | |
| Interest expense | $1446 | $1228 | $1438 | |
| Net income | ||||
| Net income | $5164 | $6668 | $8458 | |
| Income (for common shares) | $5164 | $6668 | $8458 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1548 | -$277 | $1029 | |
| Operating activities | ||||
| Depreciation | $738 | $741 | $765 | |
| Business acquisitions & disposals | -$4 | |||
| Stock-based compensation | ||||
| Total cash flows from operations | $265 | $4840 | $1467 | |
| Investing activities | ||||
| Capital expenditures | -$370 | -$300 | -$365 | |
| Investments | -$32 | -$83 | $144 | |
| Total cash flows from investing | -$1911 | -$640 | -$495 | -$440 |
| Financing activities | ||||
| Dividends paid | -$1183 | -$392 | -$401 | -$358 |
| Sale and purchase of stock | -$950 | -$3841 | -$470 | |
| Net borrowings | -$893 | $1888 | -$286 | |
| Total cash flows from financing | -$4399 | -$2309 | -$2529 | -$1250 |
| Effect of exchange rate | $6 | -$3 | -$9 | $14 |
| Change in cash and equivalents | -$1153 | -$2687 | $1807 | -$209 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5164 | $6668 | $5365 | $8458 |
| Operating activities | ||||
| Depreciation | $3035 | $2937 | $2923 | $2802 |
| Business acquisitions & disposals | -$434 | $4835 | -$1894 | $5453 |
| Stock-based compensation | ||||
| Total cash flows from operations | $11813 | $8656 | $7191 | $10350 |
| Investing activities | ||||
| Capital expenditures | -$1573 | -$1295 | -$1154 | -$1094 |
| Investments | -$2835 | -$272 | -$660 | -$1406 |
| Total cash flows from investing | -$5174 | $3098 | -$3611 | $2976 |
| Financing activities | ||||
| Dividends paid | -$1450 | -$1384 | -$1341 | |
| Sale and purchase of stock | -$2097 | -$7218 | -$7416 | -$3666 |
| Net borrowings | -$278 | -$2559 | $521 | -$4736 |
| Total cash flows from financing | -$4294 | -$11240 | -$8212 | -$8533 |
| Effect of exchange rate | $16 | -$86 | -$65 | $41 |
| Change in cash and equivalents | $2361 | $428 | -$4697 | $4834 |
News
|
Here's Why Cigna (CI) is a Strong Value Stock
Zacks · via Yahoo Finance
25 Nov 2024
|
|
Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit...
Benzinga · via AOL
3 Nov 2024
|
|
Cigna Corporation (CI): A Buzzing AI Health Stock to Add to Your Portfolio
Insider Monkey · via Yahoo Finance
3 Oct 2024
|
|
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
Zacks · via Yahoo Finance
22 Jun 2024
|
|
It’s obscene: Inside the Medicare Advantage sham
The Raw Story
30 May 2024
|
|
Parallel Advisors LLC Reduces Stock Holdings in Monster Beverage Co. (NASDAQ:MNST)
ETF DAILY NEWS
28 May 2024
|
|
Select Medical's (SEM) Shares Up 12.9% Since Q1 Earnings Beat
Zacks via Yahoo Finance
7 May 2024
|
|
Here's Why Cigna (CI) is a Strong Growth Stock
Zacks via Yahoo Finance
7 May 2024
|
|
U.S. expands federal health coverage for DACA immigrants (NYSE:UNH)
Seeking Alpha
4 May 2024
|
|
Cigna Corporation (NYSE:CI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
3 May 2024
|
Fundamentals
| Market cap | $90.11B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 279.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 29.86% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 2.30 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.86 |
| Quick ratio | 0.77 |